2023
miR-122 and miR-21 are Stable Components of miRNA Signatures of Early Lung Cancer after Validation in Three Independent Cohorts
Zyla J, Dziadziuszko R, Marczyk M, Sitkiewicz M, Szczepanowska M, Bottoni E, Veronesi G, Rzyman W, Polanska J, Widlak P. miR-122 and miR-21 are Stable Components of miRNA Signatures of Early Lung Cancer after Validation in Three Independent Cohorts. Journal Of Molecular Diagnostics 2023, 26: 37-48. PMID: 37865291, DOI: 10.1016/j.jmoldx.2023.09.010.Peer-Reviewed Original ResearchConceptsEarly lung cancerLung cancerLung cancer screening studyMiR-122MiR-21MiRNA signatureCancer screening studyLung cancer developmentPlasma miRNA signatureScreening studyIndependent cohortDiagnostic biomarkersPotential biomarkersCancer typesCohortCancer developmentCancerHealthy participantsMiR-144MiRNA panelDiagnostic potentialBiomarkersAdenocarcinomaDifferent cohortsMiRNAs
2017
Serum lipid profile discriminates patients with early lung cancer from healthy controls
Ros-Mazurczyk M, Jelonek K, Marczyk M, Binczyk F, Pietrowska M, Polanska J, Dziadziuszko R, Jassem J, Rzyman W, Widlak P. Serum lipid profile discriminates patients with early lung cancer from healthy controls. Lung Cancer 2017, 112: 69-74. PMID: 29191603, DOI: 10.1016/j.lungcan.2017.07.036.Peer-Reviewed Original ResearchConceptsEarly lung cancerSerum lipid profileLung cancerNegative predictive valuePredictive valueCancer patientsLipid profileComputed tomography lung cancer screeningLow-dose computed tomography (LDCT) lung cancer screeningTomography lung cancer screeningEarly-stage lung cancerHealthy participantsEarly lung cancer patientsLow-dose computed tomographyHigh-risk smokersLung cancer screeningLung cancer patientsStage lung cancerMaximum negative predictive valueBlood-based biomarkersPositive predictive valueSerum lipidomeCancer screeningHealthy controlsSerum signature
2016
Serum mass profile signature as a biomarker of early lung cancer
Widlak P, Pietrowska M, Polanska J, Marczyk M, Ros-Mazurczyk M, Dziadziuszko R, Jassem J, Rzyman W. Serum mass profile signature as a biomarker of early lung cancer. Lung Cancer 2016, 99: 46-52. PMID: 27565913, DOI: 10.1016/j.lungcan.2016.06.011.Peer-Reviewed Original ResearchConceptsEarly lung cancerLung cancerNegative predictive valuePredictive valueComputed tomographyEarly-stage lung cancerLow-dose computed tomographyIndeterminate pulmonary nodulesStage lung cancerPotential clinical usefulnessPositive predictive valueValidation cohortHealthy controlsClinical usefulnessDiscovery cohortBlood samplesIndependent cohortWeight serum fractionsPulmonary nodulesIndependent sample setCancerPatientsHealthy participantsMolecular biomarkersCohort